The Valley Desk

Healthcare research from Johnson & Johnson, page 10

A filtered view. Show the full list.

Refine

817 publications and 7 software projects · listings 217–240

Listings

  1. ArticleLupus science & medicine

    Demographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Disease researchAdded

  2. Clinical trial reportRMD open

    Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  3. Clinical trial reportClinical cancer research : an official journal of the American Association for Cancer Research

    Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  4. ArticleClinical cancer research : an official journal of the American Association for Cancer Research

    Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  5. ArticleCancer immunology research

    Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  6. ArticleBlood cancer discovery

    A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  7. ArticleBlood cancer discovery

    Preclinical characterization of the potent and selective MALT1 inhibitor safimaltib in B-cell lymphoma models

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Disease researchAdded

  8. ArticleInflammatory intestinal diseases

    Efficacy and Safety of Ustekinumab in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Subpopulation Analysis of UNIFI Long-Term Extension through 4 Years

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  9. ArticleCirculation. Heart failure

    Cost of Idling: Skeletal Muscle Myosin ATPase Dysfunction and the Energetic Basis of Exercise Intolerance in HFrEF

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Disease researchAdded

  10. LetterThe American journal of psychiatry

    Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  11. ArticleFocus (American Psychiatric Publishing)

    Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  12. ArticleMedical care research and review : MCRR

    Exploring Associations Between 340B Participation and Hospital Consolidation

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Public healthAdded

  13. ArticleInternational journal of toxicology

    An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  14. ArticleAntiviral therapy

    Liver concentrations of JNJ-73763989 siRNA triggers in patients with chronic hepatitis B (CHB): The INSIGHT study panel 3 results

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  15. ArticleTherapeutic advances in medical oncology

    Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  16. ArticleJournal of aerosol medicine and pulmonary drug delivery

    Identification of an Inhaled Pulmonary Selective PDGFR Inhibitor with Sustained Target Engagement

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  17. ArticleTherapeutic advances in hematology

    Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  18. ArticleDigital health

    IDEA-FAST clinical study protocol: Identifying digital end-points of fatigue, sleep quality and daytime sleepiness in N = 2000

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  19. ArticleJournal of psoriasis and psoriatic arthritis

    Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  20. ArticleBlood

    Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  21. Clinical trial reportBlood

    Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis

    Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania. Affiliation source

    Clinical careAdded

  22. ArticleBlood

    Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  23. Clinical trial reportBlood advances

    Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  24. Clinical trial reportBlood advances

    Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded